GLUCOTRACK INC (NASDAQ: GCTK)

Introduction

GlucoTrack Inc. is a medical technology company focused on the design, development, and commercialization of a fully implantable continuous blood glucose monitoring (CBGM) system. The company trades on the NASDAQ under the ticker GCTK. As of June 12, 2025, the stock closed at $0.1076, down 32.75% for the day, on a volume of 5,555,237 shares.

Corporate Structure

• Headquarters: Rutherford, New Jersey
• Industry: Medical Equipment Manufacturing
• Company Size: 11–50 employees
• Key Executives:
  • Paul V. Goode, PhD – President & Chief Executive Officer
  • Peter Wulff – Chief Financial Officer (appointed March 2025)
  • Ted Williams – Vice President, Regulatory Affairs
  • Sandra Martha – Vice President, Clinical Operations
• Medical Advisory Board:
  • Guillermo Umpierrez, MD, CDCES, FACE, MACP (appointed February 26, 2025)
  • Victoria Carr-Brendel, PhD (appointed May 2025)

Recent Developments and News

• June 12, 2025: Announced a 1-for-60 reverse stock split effective at the opening of trading on June 16, 2025.
• June 4, 2025: Presented safety and performance data at the Innovation Hub Poster session, highlighting insights from the monitoring system.
• May 28, 2025: Appointed a new executive with experience in medical devices to support the development of the CBGM.
• May 20, 2025: Formed a Patient Advisory Board to inform the design and trial protocols for the implantable CBGM.
• May 14, 2025: Confirmed plans to begin implanting patients in a multicenter feasibility study in Australia in Q3 2025; FDA Investigational Device Exemption (IDE) approval is anticipated in Q4 2025.
• May 13, 2025: Received ethical approval from St. Vincent’s Hospital for a long-term clinical evaluation of the implantable CBGM.
• April 16, 2025: Announced integration of the CBGM with an automated insulin delivery system for a major study in Europe.
• April 3, 2025: Entered an agreement with OneTwo Analytics to apply AI-driven analytics to ongoing clinical study data.
• March 31, 2025: Reported full-year 2024 financial results, noting progression from preclinical to clinical stages and securing ISO 13485:2016 certification.
• March 19, 2025: Presented first-in-human trial data at the ATTD Conference in Amsterdam.
• February 26, 2025: Named Guillermo Umpierrez, MD, CDCES, FACE, MACP to the Medical Advisory Board.

Financial and Strategic Analysis

Stock and Market Metrics (as of June 12, 2025)

Metric	Value
Share Price	$0.1076
Daily Change	–32.75%
Volume	5,555,237
Market Capitalization (intraday)	$3.08 million¹
52-Week Range	$0.10 – $62.60
Price/Book (MRQ)	0.63
Beta (5Y Monthly)	–0.19

¹ Source: Yahoo Finance

Income Statement & Cash Flow (TTM)

• Net Loss: $26.5 million
• Diluted EPS: –$57.38
• Levered Free Cash Flow: –$8.06 million

Balance Sheet (MRQ)

• Total Cash: $9.1 million
• Total Debt/Equity: 3.61%

Funding and Runway

• Secured $16.3 million from November 2024 through March 2025 to support clinical milestones.
• Cash runway is expected to cover near-term product development and regulatory activities through Q4 2025.

Strategic Initiatives

• Clinical Pipeline: Completed first-in-human CBGM study with no serious adverse events; subsequent phases and studies anticipated in 2025.
• Regulatory Path: IDE application to FDA targeted for Q4 2025; CE-mark pathway in Europe under evaluation.
• Partnerships: Collaboration with OneTwo Analytics for data insights; engagement with diabetes research centers for integrated device trials.

Market Position and Industry Context

• Addressable Market: Rising global prevalence of diabetes has increased demand for accurate and long-term monitoring solutions.
• Competitive Landscape: Competes with established continuous glucose monitoring providers (e.g., Abbott, Dexcom) by offering a fully implantable device without external wearables.
• Differentiators:
  • Multi-year implantable sensor lead placed via a standard cardiovascular procedure
  • Real-time direct-blood glucose measurement
  • Elimination of external transmitters and daily calibrations

tl;dr

• GCTK shares dropped 32.75% to $0.1076 on heavy volume (5.6 million) on June 12, 2025.
• A 1-for-60 reverse stock split becomes effective June 16, 2025.
• First-in-human CBGM study reported no serious adverse events; next patient implants planned in Australia in Q3 2025.
• FDA IDE approval for the long-term implantable system expected in Q4 2025.
• Company holds $9.1 million in cash, raised $16.3 million since November 2024; focus remains on clinical progression and regulatory filings.